AstraZeneca (NASDAQ: AZN) reported Q3 Core EPS of $1.08. Revenue for the quarter came in at $9.87 billion versus the consensus estimate of $9.87 billion.

GUIDANCE:

AstraZeneca sees FY2021 Core EPS of $5.05-$5.40, versus the consensus of $3.27.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.